81 completed, 32 unknown, 26 recruiting, 18 terminated. 189 Phase 1, 81 Phase 2.
Follow Otorhinolaryngologic Neoplasms: new trials by email Literature Review of Otorhinolaryngologic Neoplasms trials Research Report on Otorhinolaryngologic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Proactively Intervening On Early Cranial Nerve Injury As A Delayed Sequela Of Oropharyngeal Cancer: A Randomized Feasibility Clinical Trial For Pro-Habilitation (proNERVE RCT) Prednisone, Ajovy, Manual Therapy - Cranial Nerve Injury, Oropharyngeal Cancer | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 48 | 2027-03-01 | 2026-09-21 |
| Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma Biospecimen Collection, Camonsertib, Computed Tomography - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 39 | 2027-02-13 | 2026-10-29 |
| Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer SX-682, DTX - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 120 | 2026-11-04 | 2026-10-30 |
| TMV Vaccine Alone or With Toripalimab-tpzi for Recurrent Head and Neck Squamous Cell Carcinoma TMV Vaccine, Toripalimab-tpzi - Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma of Head and Neck (SCCHN) | Phase 1 | Recruiting | Metaclipse Therapeutics Corporation | 30 | 2026-10-01 | 2026-10-27 |
| Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC) Hypofractionated Stereotactic Body Radiotherapy (SBRT), Pembrolizumab, Ficerafusp alfa - Head and Neck Squamous Cell Carcinoma, HPV-Negative Squamous Cell Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Washington University School of Medicine | 45 | 2026-09-30 | 2026-08-13 |
| A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma Cemiplimab, Fianlimab - Nasopharyngeal Carcinoma, Nasopharyngeal Cancer | Phase 1 | Not yet recruiting | Memorial Sloan Kettering Cancer Center | 60 | 2026-09-01 | 2026-08-11 |
| Thermotherapy for Head and Neck Cancer Patients Thermotherapy, Radiotherapy, Concurrent chemoradiation - Head and Neck Cancer, Oropharyngeal Carcinoma | Phase 1 | Recruiting | Erasmus Medical Center | 30 | 2026-09-01 | 2026-09-02 |
| A Study of BL-M08D1 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma and Other Solid Tumors BL-M08D1 - Nasopharyngeal Carcinoma (NPC), Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 30 | 2026-09-01 | 2026-09-14 |
| Luvometinib in Combination With Serplulimab for NF2-Related Tumors Luvometinib, Serplulimab - NF2-related Schwannomatosis, NF2 | Phase 1 / Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 30 | 2026-07-31 | 2026-07-16 |
| A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors ARV-6723, Pembrolizumab, SOC - Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | Arvinas Inc. | 499 | 2026-07-29 | 2026-10-13 |
| Study to Determine Optimal Dose, Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II Trineumin - Neurofibromatosis Type II, NF2 | Phase 1 / Phase 2 | Not yet recruiting | PRG Science & Technology Co., Ltd. | 25 | 2026-07-01 | 2026-01-23 |
| Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors Becotatug Vedotin - Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Nasopharyngeal Carcinoma | Phase 1 | Recruiting | Sun Yat-sen University | 51 | 2026-05-30 | 2026-05-13 |
| Integrating Allogeneic NK Cells in High-risk Advanced Stage III-IV Nasopharyngeal Cancer Patients Allogenic expanded Natural Killer Cells (AlloNK1) - Nasopharyngeal Carcinoma (NPC), Minimal Residual Disease | Phase 1 / Phase 2 | Not yet recruiting | Singapore General Hospital | 31 | 2026-04-01 | 2026-03-30 |
| Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. Chidamide, Toripalimab, Anlotinib - Nasopharyngeal Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Sun Yat-sen University | 52 | 2026-03-31 | 2026-03-20 |
| Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck Tumors EDS01 1.0×10^11 VP + Toripalimab, EDS01 5.0×10^11 VP + Toripalimab, EDS01 1.0×10^12 VP + Toripalimab - Head & Neck Cancer, Nasopharyngeal Cancinoma (NPC) | Phase 1 | Recruiting | West China Hospital | 9 | 2026-03-27 | 2026-09-02 |
| A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma. YL201, Toripalimab, Cisplatin - Recurrent or Metastatic Nasopharyngeal Carcinoma | Phase 1 / Phase 2 | Recruiting | MediLink Therapeutics (Suzhou) Co., Ltd. | 202 | 2025-11-05 | 2025-12-02 |
| SSTR2 Imaging With [68Ga]Ga-DOTA-TOC PET/CT in NPC [68Ga]Ga-DOTA-TOC PET imaging - Nasopharyngeal Carcinoma (NPC) | Phase 1 / Phase 2 | Recruiting | University Medical Center Groningen | 10 | 2025-09-25 | 2025-10-03 |
| [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers [212Pb]VMT-alpha-NET, [203Pb]VMT-alpha-NET, 68Ga-DOTATATE - Sinonasal Neuroendocrine Carcinoma, Nasopharyngeal Carcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 120 | 2025-08-19 | 2026-10-06 |
| E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers E7 TCR-T cells, Aldesleukin - HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma | Phase 1 / Phase 2 | Recruiting | Christian Hinrichs | 15 | 2025-08-11 | 2026-10-28 |
| EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma EGFR Antibody, PD-1 antibody, Gemcitabine, Cisplatin - Nasopharyngeal Cancinoma (NPC), Recurrent Nasopharynx Carcinoma | Phase 1 / Phase 2 | Recruiting | Sun Yat-sen University | 148 | 2025-07-09 | 2026-05-11 |
Showing 20 of 189. Sign in to see all of them.
Nasopharyngeal Carcinoma (76) · Oropharyngeal Neoplasms (56) · Head and Neck Neoplasms (53) · Squamous Cell Carcinoma of Head and Neck (49) · Nasopharyngeal Neoplasms (47) · Laryngeal Neoplasms (40) · Mouth Neoplasms (32) · Hypopharyngeal Neoplasms (29) · Carcinoma, Non-Small-Cell Lung (25) · Uterine Cervical Neoplasms (23) · Breast Neoplasms (18) · Carcinoma, Renal Cell (18) · Stomach Neoplasms (17) · Carcinoma (16) · Ovarian Neoplasms (16)
Otorhinolaryngologic Diseases (188) · Neoplasms by Site (183) · Neoplasms (178) · Pharyngeal Diseases (169) · Stomatognathic Diseases (169) · Pharyngeal Neoplasms (160) · Neoplasms by Histologic Type (143) · Neoplasms, Glandular and Epithelial (134) · Head and Neck Neoplasms (128) · Carcinoma (115) · Nasopharyngeal Diseases (113) · Respiratory Tract Diseases (68) · Nasopharyngeal Neoplasms (67) · Respiratory Tract Neoplasms (67)
Cisplatin (24) · pembrolizumab (20) · Gemcitabine (13) · Radiotherapy (12) · Cyclophosphamide (8) · toripalimab (8) · fludarabine (7) · Fluorouracil (6) · Paclitaxel (6) · Radiotherapy, Intensity-Modulated (6) · Biopsy (5) · Cetuximab (5) · Radiation (5) · Specimen Handling (5) · Bevacizumab (4)
National Cancer Institute (NCI) (17) · Sun Yat-sen University (11) · Baylor College of Medicine (7) · M.D. Anderson Cancer Center (5) · National University Hospital, Singapore (5) · Fuda Cancer Hospital, Guangzhou (4) · Memorial Sloan Kettering Cancer Center (4) · Incyte Corporation (3) · Jiangsu HengRui Medicine Co., Ltd. (3) · Shanghai Proton and Heavy Ion Center (3) · West China Hospital (3) · Xencor, Inc. (3) · Cancer Research UK (2) · Dana-Farber Cancer Institute (2) · Erasmus Medical Center (2)
United States (102) · China (48) · Singapore (12) · Canada (9) · France (7) · Netherlands (7) · Taiwan (7) · United Kingdom (7) · Hong Kong (6) · South Korea (6) · Spain (6) · Australia (4) · Japan (4) · Belgium (3) · Denmark (3)
Charalampos Floudas, M.D. (3) · Jiade J Lu, MD (3) · Stephen Gottschalk, MD (3) · Boon Cher Goh (2) · Hassan Arshad, MD (2) · Jibing Chen, MD, PhD (2) · Michiel Kroesen, MD, Dr. (2) · Yvonne M Mowery (2) · A. Dimitrios Colevas, MD (1) · Aaron Tward, MD (1) · Aditi Mehta, DO (1) · Amit Agrawal (1)
PMID 42580817, PMID 11127145, PMID 14710949, PMID 15033677, PMID 15542583, PMID 16597660, PMID 16672085, PMID 18971421, PMID 21246519, PMID 22847995, PMID 23083061, PMID 2350571, PMID 25407966, PMID 25965900, PMID 26062933, PMID 26186556, PMID 26416517, PMID 26611425, PMID 27411683, PMID 28054442, PMID 28253270, PMID 28498880, PMID 28835441, PMID 29388200, PMID 29438373, PMID 30213452, PMID 30255106, PMID 30702598, PMID 30850872, PMID 31236579, PMID 31500595, PMID 31684993, PMID 31796519, PMID 31907401, PMID 32027620, PMID 32479189, PMID 32934330, PMID 32987138, PMID 33004905, PMID 33120792, PMID 33161013, PMID 33433743, PMID 33492986, PMID 33613701, PMID 34841093, PMID 35098345, PMID 35623069, PMID 36041429, PMID 36412064, PMID 36787089
2019 (3), 2018 (2), UM1CA186690 (2), 2009 (1), 2015 (1), 2017 (1), 2023 (1), 2025 (1), N01CM62201 (1), P01CA094237 (1), P30CA008748 (1), P30CA014520 (1), P30CA015704 (1), P30CA016672 (1), P30CA023074 (1)